Key facts
- RainPath AI’s last known valuation is $10.2M (Jul 2025).
- It has raised $2.9M; the latest was Accelerator/Incubator in Dec 2025.
- Notable investors include 21st by CentraleSupélec, Advans Lab, Teampact Ventures, Épopée Gestion.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for RainPath AI
- ·The full record, as it builds
Funding rounds
No funding rounds for RainPath AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RainPath AI
Developer of pathology automation tools designed to help with human tissue analysis through AI. The company's tools offer to streamline the diagnostic workflows with fully virtual staining, smarter slide analysis, and report generation, without any chemicals, technicians, or bottlenecks, enabling healthcare centers to improve testing efficiency and save time.
- Sector
- Healthcare
- HQ
- La Mézière, France
- Founded
- 2025
- Employees
- 9
- Website
- rainpath.ai/
- Ownership
- Privately Held (backing)
RainPath AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RainPath AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RainPath AI in its N-PORT filings yet. We sweep new filings monthly.